Literature DB >> 17079808

Is septal glucose metabolism altered in patients with left bundle branch block and ischemic cardiomyopathy?

Kerry Thompson1, George Saab, David Birnie, Benjamin J W Chow, Heikki Ukkonen, Karthik Ananthasubramaniam, Robert A Dekemp, Linda Garrard, Terrence D Ruddy, Jean N Dasilva, Rob S B Beanlands.   

Abstract

UNLABELLED: Left bundle branch block (LBBB) is common in patients with heart failure (HF) and contributes to left ventricular (LV) dysfunction. The abnormal septal motion may alter septal metabolic demand but this has not been well characterized in patients with ischemic cardiomyopathy (ICM) and LV dysfunction. The aim of this study was to determine the effect of LBBB on septal metabolism in patients with ICM, LV dysfunction, and LBBB.
METHODS: Fifty-three patients with LV dysfunction and ICM were identified: 34 with LBBB, 19 with normal QRS (</=100, control patients). PET using (18)F-FDG and (82)Rb was used to measure myocardial glucose metabolism and perfusion, respectively. Perfusion-metabolism differences were determined. Scar scores (matched decreases in (18)F-FDG and (82)Rb), mismatch scores (hibernating myocardium with decreased (82)Rb relative to (18)F-FDG), and reverse-mismatch (R-MM) scores (reduced (18)F-FDG relative to (82)Rb) were assessed in the septum and lateral wall.
RESULTS: (18)F-FDG uptake in the septum was reduced in patients with LBBB (64.0% +/- 15.4%) compared with control patients (74.9% +/- 14.3%; P < 0.05). Mean septal R-MM was greater in patients with LBBB (19.1% +/- 15.3%) versus control patients (4.7% +/- 10.6%; P < 0.05). However, 32% (11/34) of patients with LBBB did not demonstrate septal R-MM, 91% (10/11) of whom demonstrated lateral wall perfusion defects. Of the 68% (23/34) of patients with LBBB and septal R-MM, 52% (12/23) demonstrated lateral wall perfusion defects (P < 0.05). There was a significant difference in the percentage of the lateral wall with scar between those with septal R-MM (9.3% +/- 10.5%) and those without (19.9% +/- 14.3%; P < 0.05).
CONCLUSION: Previously, LBBB was believed to be characterized by reduced glucose metabolism relative to perfusion in the septum; however, this is not always the case in ICM. LBBB is not associated with septal R-MM in >30% of this patient population. Absence of this finding was often associated with lateral wall perfusion defects, suggesting an alteration in the metabolic demand on the septum. This may have implications for HF therapies such as resynchronization and requires further study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079808

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Reduced septal glucose metabolism predicts response to cardiac resynchronization therapy.

Authors:  David Birnie; Rob A de Kemp; Anthony S Tang; Terence D Ruddy; Michael H Gollob; Ann Guo; Kathryn Williams; Kerry Thomson; Jean N DaSilva; Rob S Beanlands
Journal:  J Nucl Cardiol       Date:  2011-12-10       Impact factor: 5.952

Review 2.  Multimodality Imaging of Myocardial Viability.

Authors:  Kinjan Parikh; Alana Choy-Shan; Munir Ghesani; Robert Donnino
Journal:  Curr Cardiol Rep       Date:  2021-01-04       Impact factor: 2.931

3.  Altered myocardial glucose utilization and the reverse mismatch pattern on rubidium-82 perfusion/F-18-FDG PET during the sub-acute phase following reperfusion of acute anterior myocardial infarction.

Authors:  Daniel D Anselm; Anjali H Anselm; Jennifer Renaud; Harold L Atkins; Robert de Kemp; Ian G Burwash; Kathryn A Williams; Ann Guo; Cathy Kelly; Jean Dasilva; Rob S B Beanlands; Christopher A Glover
Journal:  J Nucl Cardiol       Date:  2011-05-13       Impact factor: 5.952

4.  An abbreviated hyperinsulinemic-euglycemic clamp results in similar myocardial glucose utilization in both diabetic and non-diabetic patients with ischemic cardiomyopathy.

Authors:  James A Fallavollita; Andrew J Luisi; Edward Yun; Robert A deKemp; John M Canty
Journal:  J Nucl Cardiol       Date:  2010-04-14       Impact factor: 5.952

5.  Microvascular function, is there a link to myocardial viability: Is this another piece to the puzzle?

Authors:  Fernanda Erthal; Natasha Aleksova; Aun Yeong Chong; Robert A de Kemp; Rob S B Beanlands
Journal:  J Nucl Cardiol       Date:  2016-07-05       Impact factor: 5.952

6.  ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures.

Authors:  Vasken Dilsizian; Stephen L Bacharach; Rob S Beanlands; Steven R Bergmann; Dominique Delbeke; Sharmila Dorbala; Robert J Gropler; Juhani Knuuti; Heinrich R Schelbert; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2016-07-08       Impact factor: 5.952

Review 7.  Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow?

Authors:  Robert A deKemp; Keiichiro Yoshinaga; Rob S B Beanlands
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

Review 8.  Acquisition, Processing, and Interpretation of PET 18F-FDG Viability and Inflammation Studies.

Authors:  Emel Celiker-Guler; Terrence D Ruddy; R Glenn Wells
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

9.  Ventricular phase analysis moves on to the next phase: What technologists should keep in mind.

Authors:  Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2020-06-17       Impact factor: 5.952

Review 10.  Series of myocardial FDG uptake requiring considerations of myocardial abnormalities in FDG-PET/CT.

Authors:  Ryogo Minamimoto
Journal:  Jpn J Radiol       Date:  2021-01-31       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.